Amsterdam—First-line treatment with ribociclib plus letrozole prolongs progression-free survival (PFS) in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer and is as safe as it is for younger women, according to a subset analysis of the MONALEESA-2 trial.
Data on this subset of 295 women older than 65 years were presented at the 2017 annual meeting of the European Cancer Congress. (The results for all 668 patients in the randomized, Phase III